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Abstract
 
Mucosal secretions of the human gastrointestinal, respiratory, and genital tracts contain the
immunoglobulins (Ig)G and secretory IgA (sIgA) that function together in host defense. Ex-
actly how IgG crosses epithelial barriers to function in mucosal immunity remains unknown.
Here, we test the idea that the MHC class I–related Fc-receptor, FcRn, transports IgG across
the mucosal surface of the human and mouse lung from lumen to serosa. We find that bron-
chial epithelial cells of the human, nonhuman primate, and mouse, express FcRn in adult-life,
and demonstrate FcRn-dependent absorption of a bioactive Fc-fusion protein across the respi-
ratory epithelium of the mouse in vivo. Thus, IgG, like dimeric IgA, can cross epithelial barri-
ers by receptor-mediated transcytosis in adult animals. These data show that mucosal surfaces
that express FcRn reabsorb IgG and explain a mechanism by which IgG may act in immune
surveillance to retrieve lumenal antigens for processing in the lamina propria or systemically.
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Introduction
 
Host defense against infection at mucosal surfaces depends
on humoral immunity (1). Both IgA and IgG contribute
(2–5). In the human intestine, lung, and genitourinary tract,
a single layer of columnar epithelial cells forms the protec-
tive barrier between host and environment (6). IgA crosses
this barrier to function in lumenal secretions by binding the
polymeric Ig receptor (pIgR). The pIgR mediates vesicular
transport of dimeric IgA for secretion across the epithelial
cell in a process termed transcytosis (7). Some mucosal se-
cretions in humans also contain IgG, where it functions to-
gether with sIgA in host defense (4, 8). In humans, IgG
concentrations predominate over sIgA in the lumen of the
lower respiratory and female genital tracts (9, 10), and rectal
secretions contain IgG in concentrations that may exceed
700 
 
 
 
g/ml (11). Systemically administered IgG protects
against mucosal infection by respiratory syncytial virus in
the human lung (12) and HIV in the monkey intestine and
vagina (5, 13). Humans deficient in IgG exhibit an in-
creased incidence and severity of mucosal and systemic in-
fections, and in particular of infections caused by microbes
that invade or colonize the respiratory tract. The mecha-
nism, however, by which IgG may cross epithelial barriers
to function in mucosal secretions remains unknown.
In the intestine of suckling rodents and in the human
placenta, the MHC class I–related Fc-receptor for IgG,
FcRn, mediates transport of IgG across epithelial barriers
by transcytosis. Transepithelial transport by FcRn explains
how humoral immunity transfers from mother to infant.
After weaning, however, epithelial cells of the rodent intes-
tine downregulate expression of FcRn to nearly undetect-
able levels, and adult rodents do not absorb orally adminis-
tered IgG. In contrast, absorptive epithelial cells lining the
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intestine of humans continue to express FcRn in adult life
(14), and when tested in vitro, human, canine, and rodent
epithelial cells in culture that express FcRn exhibit FcRn-
dependent transcytosis of IgG in both directions across the
epithelial monolayer (15–17). Based on these data, we re-
cently proposed that FcRn may function in the adult hu-
man to shuttle IgG or IgG-antigen complexes across epi-
thelial barriers for immune surveillance, host defense, or
both (15, 18).
We now report that bronchial epithelial cells of the adult
human, nonhuman primate, and mouse express FcRn. To
test for FcRn-dependent IgG transport at this site (by ex-
amining absorption from lumen to serosa), we prepared a
fusion protein consisting of the hormone erythropoietin
(Epo)
 
*
 
 attached to the Fc fragment of murine IgG1 (Epo–
Fc). Epo binds to erythroid progenitor cells in the bone
marrow and promotes proliferation of the red cell lineage.
The Fc-fragment binds specifically to FcRn. Thus, Epo–Fc
acts as a tracer to measure FcRn-dependent transepithelial
transport in vivo, assessed as a reticulocytosis 4 d after ad-
ministration of the fusion protein to mucosal surfaces. The
use of Epo as a bioactive marker for IgG transport confers a
high degree of sensitivity to the experimental approach.
Our data show that FcRn mediates the absorption of intact
Epo–Fc across the lung of the adult mouse by receptor-
mediated transcytosis. These results define a function for
FcRn at mucosal surfaces in adult animals and explain how
IgG may get reabsorbed from lumenal secretions to partici-
pate in mucosal immunity.
 
Materials and Methods
 
Preparation of Epo–Fc Fusion Proteins.
 
cDNA for full-length
mouse Epo was amplified by PCR from a plasmid provided by
T.R. Lappin (Queens University, Belfast, UK; reference 19) us-
ing the forward primer 5
 
 
 
-ATCTAGCGCGCACTCCGCTC-
CCCCCACGCCTCATC and backward primer 5
 
 
 
-GATCAT-
GTCGACCGCAGCGGCCCTGTCCCCTCTCCTGCAG to
introduce a short COOH-terminal extension (GGSGGS). The
Fc-fragment of mIgG1 containing hinge, CH2 and CH3 do-
mains was cut from cDNA provided by Christine Ambrose (Bio-
gen, Cambridge Center, Cambridge, MA). Both DNA fragments
were ligated into the vector scFvExpress-sec (provided by Jasper
zu Putlitz, Einrich Hewe University, Berlin, Germany; reference
20). Mutations were introduced into the resulting Epo-Fc con-
struct by using site-directed mutagenesis (Stratagene).
 
Protein Expression.
 
Chinese hamster ovary (CHO) cells were
transfected using Pfx-7 Lipid (Invitrogen) and selected for G418
resistance and subcloned. Recombinant proteins were purified
from CHO cell supernatants by affinity chromatography using
Protein G Sepharose 4 Fast Flow (Amersham Pharmacia Biotech).
Large quantities were prepared by National Cell Culture Center.
 
Enzyme-Linked Immunosorbent Assay.
 
Epo–Fc was measured
using a standard sandwich ELISA with anti-Epo mAb for capture
(expressed and purified from BF-11 cells obtained from American
Type Culture Collection), and goat anti–mouse Fc-HRP conju-
gated Ab for detection (Sigma-Aldrich). For in vivo studies, Epo-
Fc levels were quantitated in serum samples using an Epo ELISA
 
(Quantikine; R&D Systems) and calibrated against standard
curves of purified fusion protein.
 
Surface Plasmon Resonance.
 
Studies were performed on a BIA-
core 2000 (Biacore International AB) as described previously
(21). Flow cells of CM5 sensor chips were coupled with Epo–Fc
(444 RU), Epo-Fc/IHH (1283 RU) and Epo-Fc/LLG (2430
RU) using amine coupling. As a reference cell, one flow cell was
treated with buffer only during the coupling cycle. Recombinant
mouse FcRn (22) was injected at concentrations of 1,000 nM,
500 nM, 250 nM, 125 nM, and 62.5 nM at a flow rate of 10 
 
 
 
l/
minute in PBS pH 6.0 containing 0.01% Tween 20. After each
dissociation phase, residual FcRn was removed from the sensor
chip by injection of PBS, pH 7.2, plus 0.01% Tween. Data was
processed using either BIAevaluation 3.0 software or custom
written software (provided by Raimund Ober). All data were
zero adjusted and baseline subtracted before generating the sen-
sorgrams presented in Fig. 1, C and D.
 
SDS-PAGE and Western Blot Analysis.
 
Equal mass of recom-
binant proteins were analyzed by SDS-PAGE (10–20% gradient
gels) under reducing and nonreducing conditions, before and af-
ter reaction with PNGase F (New England Biolabs) that cleaves
NH
 
2
 
-linked oligosaccharides and detected by Western blot using
goat anti–mouse IgG-HRP for detection of Epo–Fc proteins. For
detection of FcRn, we used an affinity purified rabbit anti-pep-
tide Ab 176/190–1 (amino acids 176–190) specific to FcRn (gift
from N. Simister, Brandeis University, Waltham, MA; reference
16) followed by anti–rabbit HRP. Lysates of intestinal epithelial
cells, whole tissue, and epithelial cell lines were prepared as de-
scribed previously (14, 15).
 
In Vivo Models.
 
Female BALB/c mice 4–6 wk of age (aver-
age weight 17 g) and 10-d-old pups (average weight 7 g) from
Taconic, and for Fig. 2 D 
 
 
 
MT/
 
 
 
MT and control C57BL/6
mice from The Jackson Laboratory were maintained under
pathogen-free conditions. Mice were anaesthetized with Isoflu-
rane by inhalation and Epo–Fc fusion proteins were injected in-
traperitoneally, fed intragastrically using a ball-point needle
(once, twice, or four times 12 h apart as indicated), or adminis-
tered intranasally by instilling a total volume of 14 
 
 
 
l into the
nostrils. Intragastric (i.g.) proteins were administered with 80–400
 
 
 
g of soybean trypsin inhibitor in 100–500 
 
 
 
l carbonate buffer,
pH 8.8, for mice 10-d or 4-wks-old, respectively. Proteins ad-
ministered by nose were suspended in PBS alone. Normal mouse
IgG and chicken IgY (both from Lampire Biological Laborato-
ries) were included in the total volume where indicated. Mice
were killed by CO
 
2
 
 inhalation 8 h or 4 d later and whole blood
was obtained by cardiac puncture. All animal studies were ap-
proved by the Institutional Review Board.
 
Flow Cytometric Analysis.
 
Whole blood samples were added
to ReticOne Reagent according to the manufacturer’s instruc-
tions. Flow cytometry was performed with a Coulter Epics XL
machine. Acquisition parameters were calibrated each time by
Retic-Cal Biological Calibration and Retic-C Cell Control.
40,000 total events in the red blood cell gate were acquired and
analyzed with ReticOne automated software for percentage of
reticulocytes (all materials from Beckman Coulter).
 
Immunohistochemistry.
 
For bright field microscopy, tissues
obtained from adult mouse lung, adult human lung operative
specimens, and adult cynomolgus macaque lung (Wyeth Genet-
ics Institute) were immediately fixed in 4% paraformaldehyde
and paraffin embedded. 5-
 
 
 
m sections were treated as described
previously (23) with 5% urea for antigen retrieval, followed by
affinity purified rabbit anti-peptide Ab 176/190–1 (amino acids
176–190) specific to FcRn (16) (1:200) or equimolar preim-
 
*
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mune serum as control, biotin-conjugated goat anti–rabbit IgG,
tyramide-HRP amplification (Perkin Elmer), and counterstained
with methyl green. Images were viewed with a Zeiss-Axiophot
microscope equipped with a Spot digital camera (Diagnostic in-
struments) and captured in Adobe Photoshop (Adobe Systems
Inc.).
 
Statistical Analysis.
 
Statistical analysis was performed by
ANOVA using StatView (SAS Institute Inc.). P values 
 
  
 
0.05 by
multiple comparison procedures were considered significant.
 
Online Supplemental Material.
 
Supplemental data available at
http://www.jem.org/cgi/content/full/jem.20020400/DC1 in-
clude (a) detailed sequence primers used to introduce mutations
into the Epo-Fc, (b) immunostaining and Western blots of adult
and suckling mouse intestine for FcRn, (c) photograph of mouse
lung showing distribution of delivery of intranasal Epo-Fc/meth-
ylene blue to the respiratory tract, and (d) dose response for
reticulocytosis induced by Epo-Fc delivered intravenously to
adult mice.
 
Results
 
Characterization of the Epo–Fc Construct.
 
To test if FcRn
transports IgG across mucosal barriers in vivo, we prepared
recombinant proteins containing human Epo fused to the
Fc fragment of mouse IgG1 including the hinge, CH2 and
CH3 domains. To demonstrate specificity for FcRn, we
also prepared fusion proteins containing one, two, or three
inactivating point mutations in the FcRn-binding site of
the Fc domain (Fig. 1 A, Epo–Fc/IHH identifies the triple
mutant protein; reference 24), and fusion proteins contain-
ing three inactivating mutations in the Fc
 
 
 
R1-binding site
(Epo–Fc/LLG) (25, 26). Fc
 
 
 
R1 represents the only other
Fc-receptor known to efficiently bind and internalize mo-
nomeric IgG (27).
All fusion proteins formed disulfide-linked homodimers
of glycosylated peptides that bound specifically to protein
G indicating functional preservation of the Fc domain (Fig.
1 B, and unpublished data). In binding analyses using sur-
face plasmon resonance (BIAcore), both immobilized Epo–
Fc and Epo–Fc/LLG bound well to mouse FcRn, whereas
the IHH mutant exhibited negligible binding (Fig. 1, C
and D). When injected intraperitoneally into 10-d-old
suckling mice, both Epo–Fc and the triple mutant Epo–Fc/
IHH induced a nearly twofold increase in the reticulocyte
fraction (from 22 
 
 
 
 0.9 to 38 
 
 
 
 1.1%; Fig. 1 E). These
data show that both WT and mutant fusion proteins con-
tain functional Fc- and Epo-domains.
Epo–Fc/IHH exhibited slightly lower potency relative
to WT Epo–Fc in its ability to induce a reticulocytosis
when administered intraperitoneally (Fig. 1 E). This could
reflect an effect of the IHH mutation on the serum half-life
of the mutant protein caused by the lack of FcRn binding.
While adult rodents do not express FcRn in intestinal epi-
thelial cells, FcRn remains functional in some cell types and
acts to protect IgG from intracellular degradation by recy-
cling IgG away from digestive organelles and back into the
circulation. Such trafficking of internalized IgG by FcRn
extends IgG half-life (28) and should prolong the half-life
of the WT Epo–Fc fusion protein, but not of the IHH mu-
tant that lacks the binding site for FcRn. Thus, in all in
vivo studies described below, we addressed this variable by
demonstrating receptor-mediated transport directly using
excess IgG to block ligand-binding to FcRn, and by dou-
Figure 1. Recombinant Epo–Fc fusion proteins form glycosylated di-
sulfide linked homodimers that exhibit functional Fc- and Epo-domains.
(A) Schematic describing COOH-terminal fusion of human Epo to the
Fc fragment of mouse IgG1. Arrows indicate substitutions at amino acid
positions essential for Fc binding to FcRn and Fc R receptors as indi-
cated. (B) SDS-PAGE and Western blot analysis of WT and FcRn-bind-
ing mutant fusion proteins (IHH) under nonreducing and reducing
(DTT) conditions with and without PNGase F treatment. (C and D)
Overlaid surface plasmon resonance sensorgrams of mFcRn injected over
immobilized Epo–Fc, Epo-Fc/IHH, and Epo–Fc/LLG. mFcRn were in-
jected at concentrations of 1,000 nM, 500 nM, 250 nM, 125 nM, and 62.5 nM at a flow rate of 10  l/min (decreasing signal levels correspond to de-
creasing concentrations of mFcRn). Data show representative sensorgrams from duplicate injections, and were processed by zero adjustment and refer-
ence cell (blank flow cell) subtraction. Note that the different coupling densities of Epo–Fc (444RU) and Epo–Fc/LLG (2430 RU) result in different
signal levels. (E) Reticulocyte fraction induced by intraperitoneal injection of Epo-Fc (0.5  g/mouse, column 2, n   3), Epo-Fc/IHH (0.5, 1, or 2  g/
mouse, columns 3, 4, and 5, n   3 mice per group), or buffer alone (PBS, column 1, n   15 mice from six independent experiments). Mean   SEM.
*P   0.05 relative to PBS control. 
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ble-dosing the IHH mutant whenever possible, which ab-
rogated the loss in potency of the IHH mutant as assessed
by intraperitoneal injection (Fig. 1 E).
 
Functional Expression of FcRn in the Intestine.
 
To dem-
onstrate FcRn-dependent transport of Epo–Fc across the
intestine, we used 10-d-old suckling and 4–6-wk-old adult
BALB/c mice. Suckling mice express high levels of FcRn
in absorptive epithelial cells lining the intestine and effi-
ciently transport IgG across the intestinal barrier by FcRn-
dependent transcytosis (29, 30). Adult mice do not. In
suckling mice, i.g. administration of WT Epo–Fc induced a
dose dependent increase in reticulocyte count (Fig. 2 A,
apparent ED
 
50
 
 
 
 
 
 0.1 
 
 
 
g/animal, 
 
 
 
7 g body WT). I.g. ad-
ministration of all fusion proteins containing amino acid
substitutions in the FcRn binding site, except for the single
alanine substitution at position I253, failed to induce a de-
tectable increase in reticulocyte count, even when adminis-
tered at twice the maximal dosage (Fig. 2 B). In contrast,
the fusion protein Epo–Fc/LLG, containing inactivating
mutations in the Fc
 
 
 
R1-binding site, remained fully active
(Fig. 2 B). Intraperitoneal injection of WT Epo–Fc or
buffer alone provided positive and negative controls for
these and all other in vivo experiments (Fig. 2, B and D,
and studies described below).
To demonstrate receptor-mediated transport directly, by
a method independent of protein half-life, we examined
Epo–Fc function in the presence and absence of competing
ligand for FcRn. Competition with 200-fold excess IgG
(100 
 
 
 
g/animal, representing 
 
 
 
0.4% of total serum IgG)
completely blocked Epo–Fc activity. Epo–Fc/IHH was
completely inactive (Fig. 2 C). These studies indicate that
absorption of Epo–Fc across the intestinal epithelial barrier
of the suckling mouse depends on receptor-mediated trans-
port, likely mediated by FcRn.
To confirm specificity for FcRn-dependent transport by
a separate approach, we administered Epo–Fc to adult WT
mice that exhibit undetectable levels of FcRn in epithelial
cells of the intestine as assessed by immunohistochemistry
(reference 31 and Supplemental Data). Even when admin-
istered at very high doses (100 
 
 
 
g/animal), i.g. Epo–Fc had
no detectable effect on the reticulocyte count in adult ani-
mals (Fig. 2 D). Identical results were obtained using adult
mice homozygous for the Igh-6
 
tm1Cgn
 
 mutation (
 
 
 
MT
mice, reference 32). Homozygous 
 
 
 
MT mice lack endoge-
nous IgG, which may compete with Epo–Fc for binding to
FcRn at the mucosal surface. Thus, adult mice do not ex-
press FcRn at detectable levels and do not display FcRn-
dependent transepithelial transport in the intestine.
 
Functional Expression of FcRn in the Respiratory Tract.
 
The high concentration of IgG in lumenal secretions of the
adult human lung suggested to us that FcRn may function
in IgG transport at this site. To test this idea, we examined
the lungs of adult humans and nonhuman primates for ex-
pression of FcRn. Total cell lysates obtained from human
and cynomologus macaque lung contained a 
 
 
 
45-kD gly-
cosylated protein (
 
 
 
40-kD deglycosylated core) (Fig. 3 A)
consistent with human FcRn as assessed by SDS-PAGE
and Western blot using FcRn specific antibodies (15, 16).
Total cell lysates prepared from two human bronchial epi-
thelial cell lines also contained FcRn (Fig. 3 B). When vi-
sualized in paraffin sections by immunohistochemistry,
FcRn localized predominantly to the apical region of bron-
chial epithelial cells lining the large and small airways of
humans (Fig. 3 C, panel I) and macaques (Fig. 3 C, panel
III), similar in intracellular distribution to that of FcRn ex-
pressed in epithelial cells lining the adult human intestine
(14, 15). Alveolar tissue also exhibited staining for FcRn,
but the weakly positive reaction product could not be as-
signed to epithelial or endothelial cells specifically (Fig. 3
C, panel II). The randomly scattered intense punctate
staining observed for FcRn in alveolar sections likely repre-
sents alveolar macrophages that express FcRn at high levels
in humans (33). These results indicate that bronchial epi-
thelial cells lining the airways of both the adult human and
Figure 2. Absorption of Epo–Fc in the intestine of 10-d-old suckling
mice depends on FcRn. (A) Dose dependent increase in reticulocyte frac-
tion for Epo–Fc administered intragastrically. One of two representative
independent experiments in 10-d-old mice, mean   SD, n   2 mice per
dose. (B) Reticulocyte fractions induced by i.g. WT Epo–Fc (0.5  g/
mouse, column 2) and Epo–Fc variants containing the indicated muta-
tion(s) in the FcRn- or F R-binding sites. FcRn mutants were adminis-
tered twice to account for predicted decrease in serum half-life as
discussed in text. Orally administered PBS and intraperitoneally ad-
ministered Epo–Fc provide negative and positive control. Mean  
SEM, n   3 mice/group. (C) Reticulocyte fractions induced by i.g. WT
Epo–Fc (0.5  g/mouse) administered with 200-fold excess human IgG
(column 3) or with buffer alone (column 2), by Epo–Fc/IHH (1  g/
mouse total, column 4), and by PBS alone (column 1). One of two repre-
sentative independent experiments, mean   SEM, n   3 mice per group.
(D) Reticulocyte fractions induced by i.g. Epo–Fc (100  g/mouse, col-
umns 2 and 5) in adult C57BL/6 (columns 1–3) or homozygous  MT/
 MT mice (columns 4–6). Mean   SEM, n   3 mice/group. In all pan-
els, *P   0.05 above PBS-control baseline. 
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nonhuman primate, and possibly alveolar epithelial cells,
express FcRn.
To demonstrate FcRn function at this site, we examined
the mouse lung. As in the human and nonhuman primate,
total tissue lysates obtained from the lungs of adult mice
contained a glycosylated 49-kD band consistent with FcRn
 
as assessed by SDS-PAGE and Western blot analysis (Fig. 4
A). Bronchial epithelial cells stained positive for FcRn as
assessed by immunohistochemistry. A low level of back-
ground staining, presumed to be nonspecific based on our
functional studies (see below and Fig. 5), was also observed
in the lamina propria of the mouse using this Ab (Fig. 4 B).
Epo–Fc administered intranasally to adult BALB/c mice
induced a dose-dependent increase in reticulocyte count
(Fig. 5 A, apparent ED
 
50
 
 
 
 
 
5–10 
 
 
 
g/animal, 
 
 
 
17 g body
WT). Intranasal administration delivered the fusion pro-
teins most intensely to proximal regions of the bronchial
tree, though some fusion proteins also reached the distal
lung as assessed by visual inspection using methylene blue
as tracer (see Supplemental Data).
When delivered at 10 
 
 
 
g/animal, both Epo–Fc and the
Fc
 
 
 
RI-binding mutant Epo–Fc/LLG induced a near maxi-
mal reticulocytosis representing absorption of 1.2–1.5 
 
 
 
g
Epo–Fc, or 
 
 
 
12–15% of the administered dose as assessed
by calibration against Epo–Fc injected intravenously (Fig. 5
B, and Supplemental Data). The FcRn-binding mutant,
Epo–Fc/IHH, induced a much smaller increase in reticulo-
cyte count that differed marginally from baseline (Fig. 5 B).
To demonstrate absorption of Epo–Fc directly, we mea-
sured serum levels of Epo–Fc and Epo–Fc/IHH by ELISA
against human Epo at a time of maximal absorption, 8 h af-
ter intranasal administration (Fig. 5 C). Adult mouse lung
exhibited dose-dependent absorption of Epo–Fc that dis-
played at least fivefold greater efficiency when compared
with Epo–Fc/IHH. Serum levels at this time point depend
far less on the rate of IgG catabolism. Thus, these data con-
firm specificity for FcRn. Nonetheless, at high doses, Epo–
Fc/IHH was absorbed at detectable levels and induced a
marginal reticulocytosis, indicating the possibility of less ef-
ficient absorption by FcRn-independent mechanisms. Such
nonspecific transport of macromolecules may occur across
the alveoli of rodents (34).
Thus, to directly demonstrate receptor-mediated trans-
port of Epo–Fc across the respiratory epithelial barrier of the
mouse lung, and specificity for FcRn, we used mouse IgG
Figure 3. Expression of FcRn in bronchial epithelium of human and
cynomolgus macaque. (A) SDS-PAGE and Western blot analysis for
FcRn in total tissue lysates (170  g/lane) of adult cynomolgus macaque
lung (lanes 1 and 2), adult human lung (lanes 3 and 4), and cultured hu-
man intestinal T84 cells as positive control (lanes 5 and 6). Lanes 2, 4, and
6 represent samples treated with PGNase F. (B) SDS-PAGE and Western
blot for FcRn in total cell lysates of Calu-3 (lanes 1 and 2), BEAS-2B
(lanes 3 and 4), and T84 cell lines as positive control (lanes 5 and 6), with
and without PNGase F treatment. Representation of 2 independent ex-
periments. (C) Immunohistochemical staining for FcRn in paraffin sec-
tions of adult human bronchus (I) and alveolae (II) and bronchus of adult
cynomolgus macaque (III) using a-FcRn specific (left) and nonspecific
preimmune antibody as control (right). Original magnification: 20 , rep-
resentative of three independent experiments.
Figure 4. Expression of FcRn in bronchial epithelium of adult mice.
(A) SDS-PAGE and Western blot analysis for FcRn in total tissue lysates
(50  g/lane) of adult mouse lung (lanes 3 and 4), and neonatal mouse in-
testine (lanes 1 and 2) as positive control. Lanes 2 and 4 represent samples
treated with PGNase F. The deglycosylation product is consistent with
the hydrolysis of predicted four glycosylation sites in mouse FcRn in con-
trast to the one glycosylation site in human FcRn as seen in Fig. 3 A. (B)
Immunohistochemical staining for FcRn in paraffin sections of adult
mouse bronchus using anti-FcRn specific (top) and nonspecific preimmune
Ab control (bottom). 
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and the chicken Ig IgY in competition studies. Chicken
IgY exhibits similar structure and function to mammalian
IgG but does not bind FcRn (35). Consequently, when ap-
plied in excess, IgG should block FcRn-dependent absorp-
tion, but IgY should not. These studies showed the ex-
pected result. Mouse IgG in 650- to 2,600-fold excess (mg/
mg), representing 
 
 
 
5% of total serum IgG, inhibited each
of three separate doses of Epo–Fc administered intranasally
(Fig. 5 D). In contrast, competition with equal molar excess
IgY or BSA had no effect. These data indicate that the
 
mouse lung exhibits receptor-mediated absorption of Epo–
Fc that displays sensitivity to competition with IgG but not
IgY, a feature characteristic of FcRn.
 
Discussion
Our results show that the MHC class I–related Fc-recep-
tor for IgG, FcRn, functions to transport IgG across epithe-
lial barriers in adult life (15, 18). We find expression of
FcRn in bronchial epithelial cells of the adult human, non-
human primate, and mouse lung, and demonstrate FcRn-
dependent absorption of a bioactive Fc-fusion protein
across the respiratory epithelium of the adult mouse in vivo.
The idea that IgG may cross epithelial barriers by recep-
tor-mediated transcytosis in humans and other adult ani-
mals represents a novel concept in mucosal immunology
(15, 18). While abundant studies define the function of
FcRn as a transporting receptor for absorption of IgG
across the intestine in suckling rodents, the receptor disap-
pears from the rodent intestine after weaning at 21 d of
age. The few studies that directly examined absorption of
IgG across the intestine of the human indicated absorption
of only a small fraction (1% or less) of orally administered
IgG (36), though these results may be confounded by in-
tralumenal digestion of the IgG tracer. Most studies on the
mechanism of IgG secretion suggested nonspecific transu-
dation of serum proteins (1). On the other hand, two stud-
ies on mucosal secretions obtained from adult humans
showed a distinct distribution of IgG isotypes when com-
pared with IgG obtained from serum of the same individu-
als (37, 38). These data provide evidence for a specific
mechanism of IgG transport across epithelial barriers. With
the recent molecular identification of human FcRn (39),
its detection in epithelial cells of the adult human intestine
(14), and definition of FcRn function as a trafficking re-
ceptor for the bidirectional transcytosis of IgG in polarized
epithelial cell lines in vitro (15, 16, 18), other explanations
for IgG transport across mucosal epithelial barriers can now
be entertained.
In this study, we find that FcRn acts in vivo as a traffick-
ing receptor to transport IgG across mucosal epithelial bar-
riers of the adult mouse lung. Several lines of evidence sup-
port this conclusion. First, only IgG, and not albumin or
chicken IgY, blocked absorption of Epo–Fc. Such specific-
ity for competition of protein transport represents the fun-
damental characteristic of a receptor-mediated process, and
a feature characteristic of FcRn function (35, 40). Neither
absorption by passive diffusion through intercellular tight
junctions, nor endocytosis by fluid phase into the epithelial
cell, can explain these results. We also found that inactivat-
ing mutations in the Fc R1-binding site had no effect on
Epo–Fc activity. Thus, absorption of Epo–Fc cannot de-
pend on binding Fc R1 receptors, the only other Fc-
receptor that exhibits high affinity binding for monomeric
IgG (26). Finally, our studies using the Epo–Fc/IHH mu-
tant that cannot bind FcRn, even though potentially con-
founded by a predicted effect on protein half-life, imply
specificity for FcRn: a conclusion confirmed by our studies
Figure 5. FcRn-specific absorption of Epo–Fc across the epithelial cell
barrier of the adult mouse lung in vivo. (A) Dose dependent increase in
reticulocyte count for Epo–Fc administered intranasally. Mean   SEM,
six mice per group. *P   0.05 versus baseline. Maximal response in adult
mice  17%, see Fig. 2 D. (B) Reticulocyte fractions induced by intrana-
sal administration of fusion proteins containing functional FcRn-binding
sites, WT Epo–Fc (column 2) and Epo–Fc/LLG (column 4), by Epo–Fc/
IHH that lacks an FcRn-binding site (column 3), and by PBS alone (col-
umn 1). All fusion proteins were administered at 10  g/mouse. Mean  
SEM. n   5 for all groups except n   2 for PBS control. *P   0.05 ver-
sus baseline. (C) Absorption of Epo–Fc and Epo–Fc/IHH as assessed di-
rectly by ELISA of serum obtained 8 h after nasal administration of fusion
proteins at the indicated doses. (D) Reticulocyte fractions induced by in-
tranasal WT Epo–Fc (2  g, 1  g, or 0.5  g/mouse) administered to-
gether with 650-, 1,300-, or 2,600-fold excess mouse IgG (g/g, 1.3 mg
total dose, light gray bar) 1,300-fold excess chicken IgY (1.3 mg total
dose, dark gray bar) or nonspecific protein albumin (1.3 mg total dose,
black bars) as competing ligands, and by PBS alone (white bar). Mean  
SEM from two independent experiments *P   0.05 relative to Epo–Fc
plus albumin control. n   12 mice per group for doses of Epo–Fc 1  g/
mouse and PBS control. n   6 mice/group for all other doses of Epo–Fc.
In the absence of IgG block, absorption of 0.09–0.24  g of Epo–Fc, or
 10–18% of the administered dose was detected as assessed by calibration
against Epo–Fc injected intravenously (see Supplemental Data).309 Spiekerman et al.
using IgY, which are independent of catabolic effect. These
data indicate that IgG, like dimeric IgA, can cross epithelial
barriers of adult animals by receptor-mediated transcytosis.
Unlike IgA, however, FcRn moves IgG across epithelial
barriers in the opposite direction (if not both) to get reab-
sorbed from lumenal secretions.
Thus, the results of these studies explain how IgG, or
IgG–antigen complexes (41), or both, are reabsorbed
across mucosal surfaces to function in immune surveillance
and host defense. While it is well known that IgG binding
to FcRn displays sensitivity to pH (35), the vectorial trans-
port of IgG across epithelial barriers by FcRn does not de-
pend on transepithelial pH gradients established at epithe-
lial surfaces (42). As such, we predict that FcRn will
function in IgG transport at any mucosal surface that ex-
presses FcRn and propose that FcRn will mediate a steady-
state and dynamic distribution of IgG across these barriers
by reabsorbing IgG, with or without associated antigen,
from lumen secretions. IgG and sIgA exhibit different
functional characteristics, and by binding lumenal antigen,
IgG may complement sIgA in immunoregulatory function
at these sites. We also find that FcRn transports Epo–Fc
across epithelial barriers as a fully folded and functional
protein. These results define new technology to exploit
FcRn clinically. Here, FcRn offers an endogenous mu-
cosal receptor to absorb Fc-fusion proteins or vaccine anti-
gens across epithelial surfaces that otherwise represent im-
permeable barriers to macromolecules.
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